Faculty

Institution

Unit

Venue

Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Thoracic-Head And Neck Medical Oncology

Division Of Cancer Medicine

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

Christopher J. Logothetis is a high senior professor at The University of Texas MD Anderson Cancer Center. His research focuses on prostate cancer biology, genitourinary malignancies, and cancer pharmacology, with particular emphasis on aggressive variant prostate cancers and bone microenvironment interactions. His recent work includes investigating circulating tumor DNA fractions to predict outcomes in metastatic castration-resistant prostate cancer, optimizing PSMA-targeted radioligand therapy biomarkers, and exploring mechanisms such as PKA-driven SPP1 activation and KDM4A-mediated MYC regulation in neuroendocrine prostate cancer progression. He leads clinical trials combining carboplatin, cabazitaxel, and immunotherapy for aggressive variant disease.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

urology oncology prostate cancer cancer research cancer care genitourinary cancers prostatic disease cancer treatment pharmacology radiation oncology cancer cells cancer biology surgical oncology metastasis tumor biology medicinal research oncogenes pharmacotherapy clinical research molecular cancer medicine therapeutic targets cancer discovery cancer management cancer genomics bladder cancer endocrine-related cancers anti-cancer agents jama oncology cancer genetics bone research cellular therapy molecular diagnostics tumor targeting surgical pathology abiraterone acetate histopathology cancer growth vascular biology tumor suppressors malignant disease tumor heterogeneity active surveillance therapeutic efficacy androgen-independent prostate cancer drug targeting cancer risk metronomic chemotherapy castration-resistant prostate cancer thoracic oncology tumoral pathology metastatic prostate cancer germ cells overall survival clinical mycology prognostic biomarkers phase ii study prostate cancer cells drug trials benign prostatic hyperplasia prostate cancer progression phase ii trial advanced prostate cancer gastrointestinal oncology urological research bone metastases disease progression endocrine oncology bone health cohort studies apoptosis phase iii trial leuprolide acetate cancer prevention cancer patients ipilimumab versus placebo

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 1061: Prostate Cancer Cartography Initiative (Pcci): Integrating Genetic and Clinical Data to Explore Prostate Cancer Biomarkers. Cancer Research (2025)

clinical dataintegrating geneticbiomedical informaticsbiomarkersprostate cancer biomarkersurologycancer discoverycancer genomicsgenitourinary cancersbiostatisticsmolecular diagnosticsprostate cancerhuman genetics

Abstract 3123: Fracturing the Tumor-Bone Alliance in Metastatic Prostate Cancer With Ra-223. Cancer Research (2025)

Pablo SanchisAgustina SabaterJuan BizzottoGaston PascualNicolas AnselminoJiabin DongJun YangGaniraju ManyamBradley BroomZhongcheng ShiShixia HuangRocio SeniukEleonora DondossolaTeocharis PanaretakisJohn AraujoPeter ShepherdPatricia TroncosoNora NavoneChristopher J. LogothetisDaniel E. FrigoElba VazquezPaul CornGeraldine GueronEstefania Labanca

tumor-bone alliancecancer researchcancer biologyprostate cancermetastatic prostate cancer

Abstract 4122: Epigenetic Biomarker Identification of Each Stage During the Progression of Prostate Cancer. Cancer Research (2025)

abstract 4122epigenomicsbiomarkersepigenetic changesurologycancer discoveryprostatic diseasemolecular diagnosticsepigeneticsepigenetic biomarker identificationprostate cancercell biology

Association of Baseline and On-Treatment Ctdna Fraction With Clinical Outcomes in Patients With Mcrpc in the Psmafore Study of 177 Lu-Psma-617.. Journal of Clinical Oncology (2025)

on-treatment ctdna fractionbiomarkersradiologyclinical outcomescancer researchpsmafore studycancer imagingmolecular diagnosticsoncologypathologymolecular pathologycancer detection

Biomarkers to Optimize Psma-Targeted Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology (2025)

biomarker targetmetastasisbiomarkersradiation oncologymolecular cancerurologycancer discoveryradiopharmaceutical therapyprostatic diseasegenitourinary cancerscancer imagingpsma-targeted radioligand therapyoncologyprostate cancer

C3NIRA: Randomized Phase II Study of Carboplatin-Cabazitaxel-Cetrelimab (Anti-Pd-1) Induction Followed by Niraparib +/- Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers (Avpc).. Journal of Clinical Oncology (2025)

pharmacologycancer caremolecular cancerurologypharmacotherapycancer immunotherapytherapeutic targetsgenitourinary cancersprostatic diseasephase ii studyoncologyoncogenescancer treatmentprostate cancer

Evaluating Clinical Tools to Monitor Cardiovascular (CV) Risk in Men With Localized High-Risk or Locally Advanced Prostate Cancer (Lhrpc) Treated With Hormone Therapy (Ht).. Journal of Clinical Oncology (2025)

Neha VenkateshPankaj Kumar ChauhanKabir GrewalAna AparicioPatrick Glen PiliéSumit Kumar SubudhiPaul Gettys CornBilal Ahmed SiddiquiAmado J. ZuritaDaniel FrigoChristopher LogothetisPavlos MsaouelEfstratios KoutroumpakisAndrew Warren Hahn

epidemiologygynecologic oncologylocalized high-riskprostate cancerrisk managementcancer carecardiovascular imagingdisease risk assessmenturologybiostatisticsearly detectionclinical toolshormone therapybenign prostatic hyperplasiaadvanced prostate cancercardiovascular researchprostatic diseaseoncologyclinical researchhealth risk assessmentmedicinal researchcardiovascular disease

Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy. JCO Oncology Practice (2025)

cardiologymedicinebiomarkerscardiovascular interventionscancer caremonitor cardiovascular riskcardiovascular researchcardiovascular imagingurologypharmacotherapyprostatic diseaseoncologyclinical toolsprostate cancerhealth sciencespreventive cardiologycardiovascular disease

Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Medicine (2025)

Mohammad Jad MoussaGeorges C. TabetArlene O. Siefker‐RadtkeLianchun XiaoNathaniel R. WilsonJianjun GaoChristopher J. LogothetisPetros GrivasByron LeeAmishi Y. ShahPavlos MsaouelRoger LiLeticia Campos ClementeJianping ZhaoNizar M. TannirAshish M. KamatDonna E. HanselCharles C. GuoMatthew T. CampbellOmar Alhalabi

endocrine-related cancerscancer researchurologyurinary tracthistopathologic progressionmetastatic relapse outcomes

Kdm4A Promotes Nepc Progression Through Regulation of Myc Expression. Cancer Letters (2025)

cell signalingtranscription factorsmolecular cell biologyoncogenessignal transductioncell regulationnepc progressioncell biology

1
2
3
4
5
72
10 / page

Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Thoracic-Head And Neck Medical Oncology

Division Of Cancer Medicine

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 1061: Prostate Cancer Cartography Initiative (Pcci): Integrating Genetic and Clinical Data to Explore Prostate Cancer Biomarkers. Cancer Research (2025)

Abstract 3123: Fracturing the Tumor-Bone Alliance in Metastatic Prostate Cancer With Ra-223. Cancer Research (2025)

tumor-bone alliancecancer researchcancer biologyprostate cancermetastatic prostate cancer

Abstract 4122: Epigenetic Biomarker Identification of Each Stage During the Progression of Prostate Cancer. Cancer Research (2025)

abstract 4122epigenomicsbiomarkersepigenetic changesurologycancer discoveryprostatic diseasemolecular diagnosticsepigeneticsepigenetic biomarker identificationprostate cancercell biology

Association of Baseline and On-Treatment Ctdna Fraction With Clinical Outcomes in Patients With Mcrpc in the Psmafore Study of 177 Lu-Psma-617.. Journal of Clinical Oncology (2025)

on-treatment ctdna fractionbiomarkersradiologyclinical outcomescancer researchpsmafore studycancer imagingmolecular diagnosticsoncologypathologymolecular pathologycancer detection

Biomarkers to Optimize Psma-Targeted Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology (2025)

Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy. JCO Oncology Practice (2025)

Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Medicine (2025)

endocrine-related cancerscancer researchurologyurinary tracthistopathologic progressionmetastatic relapse outcomes

Kdm4A Promotes Nepc Progression Through Regulation of Myc Expression. Cancer Letters (2025)

cell signalingtranscription factorsmolecular cell biologyoncogenessignal transductioncell regulationnepc progressioncell biology

1
2
3
4
5
72
10 / page